Bioxcel therapeutics announces expansion of phase 2 trial of bxcl701 in de novo and treatment-emergent small-cell neuroendocrine prostate cancer

Initial findings from phase 1b/2 trial of bxcl701 in combination with keytruda met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent small-cell neuroendocrine prostate cancer (scnc)

BTAI Ratings Summary

BTAI Quant Ranking